Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Report

Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 07, 2022
  • PAGES：159
  • REPORT CODE：GMM826567
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market report explains the definition, types, applications, major countries, and major players of the Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Astellas

    • Janssen Pharmaceuticals

    • Bristol Myers Squibb

    • Kotobuki Pharmaceutical

    • Eli Lilly

    • AstraZeneca

    • Boehringer Ingelheim

    By Type:

    • Invokana (Canagliflozin)

    • Jardiance (Empagliflozin)

    • Farxiga/Forxiga (Dapagliflozin)

    • Suglat (Ipragliflozin)

    By End-User:

    • Hospital

    • Medical Research Institute

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Outlook to 2028- Original Forecasts

    • 2.2 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market- Recent Developments

    • 6.1 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market News and Developments

    • 6.2 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Deals Landscape

    7 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Raw Materials and Cost Structure Analysis

    • 7.1 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Key Raw Materials

    • 7.2 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Price Trend of Key Raw Materials

    • 7.3 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Key Suppliers of Raw Materials

    • 7.4 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Concentration Rate of Raw Materials

    • 7.5 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Cost Structure Analysis

      • 7.5.1 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Raw Materials Analysis

      • 7.5.2 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Labor Cost Analysis

      • 7.5.3 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Expenses Analysis

    8 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Export by Region (Top 10 Countries) (2017-2028)

    9 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Outlook by Types and Applications to 2022

    • 9.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Invokana (Canagliflozin) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Jardiance (Empagliflozin) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Farxiga/Forxiga (Dapagliflozin) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Suglat (Ipragliflozin) Consumption and Growth Rate (2017-2022)

    • 9.2 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Medical Research Institute Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Outlook till 2022

    • 10.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.2.2 Canada Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.2.3 Mexico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.2 UK Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.3 Spain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.4 Belgium Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.5 France Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.6 Italy Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.7 Denmark Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.8 Finland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.9 Norway Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.10 Sweden Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.11 Poland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.12 Russia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.3.13 Turkey Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.2 Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.3 India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.4 South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.5 Pakistan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.6 Bangladesh Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.7 Indonesia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.8 Thailand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.9 Singapore Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.10 Malaysia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.11 Philippines Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.4.12 Vietnam Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.2 Colombia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.3 Chile Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.4 Argentina Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.5 Venezuela Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.6 Peru Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.7 Puerto Rico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.5.8 Ecuador Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.6.2 Kuwait Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.6.3 Oman Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.6.4 Qatar Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.7.2 South Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.7.3 Egypt Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.7.4 Algeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

      • 10.8.2 New Zealand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    11 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Competitive Analysis

    • 11.1 Astellas

      • 11.1.1 Astellas Company Details

      • 11.1.2 Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.1.4 Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Janssen Pharmaceuticals

      • 11.2.1 Janssen Pharmaceuticals Company Details

      • 11.2.2 Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.2.4 Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Bristol Myers Squibb

      • 11.3.1 Bristol Myers Squibb Company Details

      • 11.3.2 Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.3.4 Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Kotobuki Pharmaceutical

      • 11.4.1 Kotobuki Pharmaceutical Company Details

      • 11.4.2 Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.4.4 Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Eli Lilly

      • 11.5.1 Eli Lilly Company Details

      • 11.5.2 Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.5.4 Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 AstraZeneca

      • 11.6.1 AstraZeneca Company Details

      • 11.6.2 AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.6.4 AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Boehringer Ingelheim

      • 11.7.1 Boehringer Ingelheim Company Details

      • 11.7.2 Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

      • 11.7.4 Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Outlook by Types and Applications to 2028

    • 12.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Invokana (Canagliflozin) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Jardiance (Empagliflozin) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Farxiga/Forxiga (Dapagliflozin) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Suglat (Ipragliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Medical Research Institute Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Outlook to 2028

    • 13.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.2.2 Canada Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.2 UK Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.3 Spain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.5 France Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.6 Italy Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.8 Finland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.9 Norway Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.11 Poland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.12 Russia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.2 Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.3 India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.3 Chile Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.6 Peru Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.6.3 Oman Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors

    • Figure of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Picture

    • Table Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Invokana (Canagliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Jardiance (Empagliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Farxiga/Forxiga (Dapagliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Suglat (Ipragliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Research Institute Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Table North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Canada Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Mexico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure Germany Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure UK Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Spain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Belgium Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure France Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Italy Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Denmark Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Finland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Norway Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Sweden Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Poland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Russia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Turkey Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table APAC Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Thailand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Singapore Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Philippines Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table South America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure Brazil Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Colombia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Chile Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Argentina Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Peru Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table GCC Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure Bahrain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Oman Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Qatar Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure Nigeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure South Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Egypt Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Algeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table Oceania Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure Australia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table Astellas Company Details

    • Table Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Table Janssen Pharmaceuticals Company Details

    • Table Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Table Bristol Myers Squibb Company Details

    • Table Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Table Kotobuki Pharmaceutical Company Details

    • Table Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Table AstraZeneca Company Details

    • Table AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Table Boehringer Ingelheim Company Details

    • Table Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Main Business and Markets Served

    • Table Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio

    • Figure Global Invokana (Canagliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Jardiance (Empagliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Farxiga/Forxiga (Dapagliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Suglat (Ipragliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Research Institute Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Table North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure Germany Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure Brazil Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure Australia Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US